Intralesional Meglumine Antimoniate for Treatment of Cutaneous Leishmaniasis Patients with Contraindication to Systemic Therapy from Rio de Janeiro (2000 to 2006)

dc.creatorVasconcellos, Érica de Camargo Ferreira e
dc.creatorPimentel, Maria Inês Fernandes
dc.creatorSchubach, Armando de Oliveira
dc.creatorOliveira, Raquel de Vasconcellos Carvalhaes de
dc.creatorAzeredo-Coutinho, Rilza Beatriz
dc.creatorSilva, Fátima da Conceicão
dc.creatorSalgueiro, Mariza de Matos
dc.creatorMoreira, João Soares
dc.creatorMadeira, Maria de Fátima
dc.creatorBaptista, Cibele
dc.creatorValete-Rosalino, Cláudia Maria
dc.date2018-11-08T14:25:42Z
dc.date2018-11-08T14:25:42Z
dc.date2012
dc.date.accessioned2023-09-26T22:11:31Z
dc.date.available2023-09-26T22:11:31Z
dc.identifierVASCONCELLOS, Érica de Camargo Ferreira e; et al. Intralesional Meglumine Antimoniate for Treatment of Cutaneous Leishmaniasis Patients with Contraindication to Systemic Therapy from Rio de Janeiro (2000 to 2006). Am. J. Trop. Med. Hyg., v.87, n.2, p. 257–260, 2012.
dc.identifier0002-9637
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/29955
dc.identifier10.4269/ajtmh.2012.11-0612
dc.identifier1476-1645
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8876023
dc.descriptionWe evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in 24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with contraindication to systemic therapy. Each treatment consisted of one to four intralesional applications of MA at 15-day intervals. Patients’ age ranged from 3 to 90 years; fourteen were females. Intralesional treatment in the absence of any relevant toxicity was successful in 20 (83.3%) patients. Three patients required additional treatment with amphotericin B and one required systemic MA. None of the patients developed mucosal lesions when followed up to 60 months. Intralesional MA is an effective and less toxic alternative treatment of patients with CL and contraindication to systemic therapy.
dc.formatapplication/pdf
dc.languageeng
dc.publisherAmerican Society of Tropical Medicine and Hygiene
dc.rightsopen access
dc.subjectAntimoniato de Meglumina Intralesional
dc.subjectTratamento
dc.subjectLeishmaniose Cutânea
dc.subjectContra-indicação
dc.subjectterapia sistêmica
dc.subjectRio de Janeiro
dc.subjectCutaneous Leishmaniasis
dc.subjectTreatment
dc.subjectIntralesional Meglumine Antimoniate
dc.subjectSystemic Therapy
dc.subjectContraindication
dc.subjectRio de Janeiro
dc.titleIntralesional Meglumine Antimoniate for Treatment of Cutaneous Leishmaniasis Patients with Contraindication to Systemic Therapy from Rio de Janeiro (2000 to 2006)
dc.typeArticle


Este ítem pertenece a la siguiente institución